Intelligence Β· Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe β grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring β€24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months β use filters for patent-cliff planning.
-
US 7199157
Use of treprostinil to improve kidney functions
granted -
US 7198947
Production of functional proteins: balance of shear stress and gravity
granted -
US 7196074
Methods of making, using and pharmaceutical formulations comprising 7Ξ±, 11Ξ²-dimethyl-17Ξ²-hydroxyestra-4, 14-dien-3-one and 17 esters thereof
granted -
US 7192593
Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
granted -
US 7192705
Transductin-1 and applications to hereditary deafness
granted -
US 7193053
Hypoxia-inducible factor 1alpha variants and methods of use
granted -
US 7193072
Compositions to identify swine genetically resistant to F18 E. coli associated diseases
granted -
US 7192934
Vaccines for blocking transmission of Plasmodium vivax
granted -
US 7189812
Human gene critical to fertility
granted -
US 7189393
Recombinant anti-tumor RNAse
granted -
US 7189513
Human papilloma virus immunoreactive peptides
granted -
US 7186698
Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat
granted -
US 7182944
Methods of increasing distribution of nucleic acids
granted -
US 7179217
Apparatus for enhancing tissue repair in mammals
granted -
US 7179621
Pigment epithelium-derived factor: sequence of the PEDF gene
granted -
US 7179899
Composite antibodies of humanized human subgroup IV light chain capable of binding to TAG-72
granted -
US 7175843
Methods for selectively stimulating proliferation of T cells
granted -
US 7176244
Use of 2-nitropropanol, 2-nitroethane, and 2-nitroethanol for control of microbial pathogens
granted -
US 7175981
Method of diagnosing stage or aggressiveness of breast and prostate cancer based on levels of fatty acid binding proteins
granted -
US 7175845
Monoclonal antibodies against ricin toxin and methods of making and using thereof
granted -
US 7175830
Imaging of drug accumulation as a guide to antitumor therapy
granted -
US 7175838
Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
granted -
US 7172869
Methods for transfecting T cells
granted -
US 7173007
Therapy for microbial infections
granted -
US 7169815
3-methoxybenzyl thiourea derivatives and improved lipid compositions containing same
granted -
US 7163673
Sunscreen reagents from hydroxy-substituted acylglycerides
granted -
US 7163935
Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same
granted -
US 7163818
Bacteriophage having multiple host range
granted -
US 7161059
Human hookworm model and method for maintaining human hookworm in a non-human primate
granted -
US 7157495
Hexahydrofuro[2,3-B]furan-3-YL-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor
granted -
US 7153866
Use of tempol for the treatment of Li-Fraumeni syndrome and ataxia telangiectasia
granted -
US 7153882
Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
granted -
US 7153947
Ixodes salivary anticomplement protein
granted -
US 7150984
Attenuated human rotavirus vaccine
granted -
US 7150875
Recombinant Plasmodium vivax merozoite protein-1 p42 vaccine
granted -
US 7151087
CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection
granted -
US 7148323
Major neutralization site of hepatitis E virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to hepatitis E virus
granted -
US 7148036
DNA molecules encoding cartilage-derived morphogenetic proteins
granted -
US 7144918
Biologically active macrolides, compositions, and uses thereof
granted -
US 7144575
Methods for selectively stimulating proliferation of T cells
granted -
US 7144986
Polypeptides comprising IL-6 ligand binding receptor domains
granted -
US 7141661
Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
granted -
US 7141589
Methods of inhibiting formation of vascular channels and methods of inhibiting proliferation
granted -
US 7141234
Imaging of drug accumulation as a guide to antitumor therapy
granted -
US 7135303
Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
granted -
US 7132420
Aspartic protease inhibitors
granted -
US 7132102
Bacteriocins and novel bacterial strains
granted -
US 7132392
Inhibition of cell motility and angiogenesis by inhibitors of Grb2-SH2-domain
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory